Theralase Technologies Inc. V.TLT

Sample size : Accelerated versus regular pathway

[N0taP00p]

I was trying to understand if a small sample size was a detriment to oncology drug approvals by the FDA.  If you search on the following text "Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018", you will find this in the article:... " we found that accelerated pathway approvals are based on significantly more single-arm studies with small sample sizes and surrogate primary endpoints. However, effect size was not different between the pathways".  

Shout out to Cancerslayer. This was what you implied also, I think.  We should know "soon" (a word that I've begun to dissect for deeper meanings of late). Sad. 

 

 

 

 

 

 

[Rumpl3StiltSkin]

Poop, As a long time holder of this stock, I've never been more sure of a great outcome, $$$$$. And it will, mostly, hapen in '23. IMO. :-)